Cystadenocarcinoma, Serous - 24 Studies Found
Recruiting |
: A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma : HER2/Neu+ Uterine Serous Carcinoma : 2015-07-02 : Drug: Afatinib Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 |
Not yet recruiting |
: Proof-of-concept Study of Birinapant in Combination With Platinum Based Chemotherapy in Subjects With High Grade Serous Carcinomas : Advanced Newly Diagnosed or Recurrent High Grade Serous Carcinomas (HGSC) : 2016-04-22 :
|
Completed |
: Papillary Serous Carcinoma of the Endometrium : Endometrial Cancer : 2007-08-09 :
|
Completed |
: A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma : Uterine Cancer : 2005-10-03 :
|
Completed |
: Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma : Uterine Cancer : 2007-07-23 :
|
Active, not recruiting |
: Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer :
|
Not yet recruiting |
: Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer :
|
Not yet recruiting |
: Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer :
|
Recruiting |
: To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers :
|
Completed |
: Phase II ABT-888 With Cyclophosphamide :
|